Related references
Note: Only part of the references are listed.Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation
Ming-Yang Lee et al.
ANNALS OF HEMATOLOGY (2008)
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
Catherine M. Bollard et al.
BLOOD (2007)
Bortezomib induce aoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells
Ping Zou et al.
JOURNAL OF VIROLOGY (2007)
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
Susan R. Perrine et al.
BLOOD (2007)
Treatment of solid organ transplant recipients with autologolus Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
Barbara Savoldo et al.
BLOOD (2006)
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
Ann M. Leen et al.
NATURE MEDICINE (2006)
EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines
Adrienne Chen et al.
JOURNAL OF VIROLOGY (2006)
Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation
Wai H. Lim et al.
NEPHROLOGY (2006)
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease
B Savoldo et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Technology Insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies
R Khanna et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Post-transplant lymphoproliferative disorders
S Gottschalk et al.
ANNUAL REVIEW OF MEDICINE (2005)
Epstein-Barr virus-associated Hodgkin's lymphoma
MK Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas
H Katano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
CM Bollard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease
CM Bollard et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
RF Little et al.
BLOOD (2003)
Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival
JC Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
T Haque et al.
LANCET (2002)
Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system
KS Slobod et al.
LANCET (2000)
Epstein-Barr virus infection.
JI Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
